Weizmann Science Park
7 Golda Meir Street
8 articles with Sol-Gel Technologies
Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced financial results for the third quarter ended September 30, 2019 and provided an update on its clinical development programs.
Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
Sol-Gel Technologies, Ltd. announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay® microencapsulated benzoyl peroxide cream, 5%, at the 39th Annual Fall Clinical Dermatology Conference® October 17-20 in Las Vegas, Nevada.
7/11/2019Companies from across Europe, Asia and around the globe share pipeline and business updates.
The Company anticipates launching the product this month.
The closing of the initial public offering is expected to occur on or about February 5, 2018, subject to customary closing conditions.